Professor, Internal Medicine, UC, Davis School of Medicine
Hematology
Dr. Joseph M. Tuscano, MD
|
|
Give Review
Joseph Tuscano works in the field of Hematology. He went to medical school at Keck School of Medicine of USC. Keck School of Medicine of USC is ranked 31 in research and 72 in primary care medicine He received awards:"CMS Meaningful Use Stage 1 Certification". Joseph Tuscano is a published doctor and has 62 publications published. The lastest was: 'GCKR links the Bcr-Abl oncogene and Ras to the stress-activated protein kinase pathway.' Joseph M. Tuscano is registered with Medicare.
Publications
- Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin Lymphoma in the modern era.
- Targeted therapy with MXD3 siRNA, anti-CD22 antibody and nanoparticles for precursor B-cell Acute lymphoblastic leukaemia.
- Histone deacetylase inhibition enhances the Lymphomacidal activity of the anti-CD22 monoclonal antibody HB22.7.
- Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin Lymphoma.
- A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory Acute myeloid leukemia or patients over the age of 60 with newly diagnosed Acute myeloid...
- Diagnosis and classification of autoimmune hemolytic Anemia.
- Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin Lymphoma who received prior stem cell transplantation.
- Targeting CD22 in B-Cell Malignancies: Current Status and Clinical Outlook.
- Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Co...
- Efficacy of a CD22-targeted antibody-saporin conjugate in a xenograft model of precursor-B cell Acute lymphoblastic leukemia.
- Efficacy and toxicity of a CD22-targeted antibody-saporin conjugate in a xenograft model of non-Hodgkin's Lymphoma.
- The CD22 Antigen is Broadly Expressed on Lung Cancer Cells and is a Target for Antibody-based Therapy.
- Disulfide cross-linked micelles for the targeted delivery of vincristine to B-cell Lymphoma.
- The HB22.7 Anti-CD22 Monoclonal Antibody Enhances Bortezomib-mediated Lymphomacidal Activity in a Sequence Dependent Manner.
- Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: a California Cancer Consortium trial.
- The Bs20x22 anti-CD20-CD22 bispecific antibody has more Lymphomacidal activity than do the parent antibodies alone.
- Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD).
- Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non-Hodgkin's Lymphoma xenograft mouse model.
- Imaging and pharmacokinetics of (64)Cu-DOTA-HB22.7 administered by intravenous, intraperitoneal, or subcutaneous injection to mice bearing non-Hodgkin's Lymphoma xenog...
- Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's Lymphoma.
- Multiple Myeloma: epidemiology and therapeutic options.
- High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast Cancer by using a MUC-1 monoclonal antibody, m170, linked to in...
- Applications of one-bead one-compound combinatorial libraries and chemical microarrays in signal transduction research.
- Anti-CD22 ligand-blocking antibody HB22.7 has independent Lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in Lymphoma xenografts.
- Acetaminophen and diphenhydramine as premedication for platelet transfusions: a prospective randomized double-blind placebo-controlled trial.
- Early diagnosis and successful treatment of a patient with transfusion-associated GVHD with autologous peripheral blood progenitor Cell transplantation.
- A comparison of multiplex suspension array large-panel kits for profiling cytokines and chemokines in rheumatoid arthritis patients.
- Dose, timing, schedule, and the choice of targeted epitope alter the efficacy of anti-CD22 immunotherapy in mice bearing human Lymphoma xenografts.
- B Cell reductive therapy with rituximab in the treatment of rheumatoid arthritis.
- B-cell depletion with anti-CD20 ameliorates autoImmune cholangitis but exacerbates colitis in transforming growth factor-beta receptor II dominant negative mice.
- Geoepidemiology and autoimmune manifestations of lymphoproliferative Disorders.
- Phosphatase inhibition augments anti-CD22-mediated signaling and cytotoxicity in non-hodgkin''s Lymphoma cells.
- Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell Lymphoma.
- Treatment of non-Hodgkin''s Lymphoma xenografts with the HB22.7 anti-CD22 monoclonal antibody and phosphatase inhibitors improves efficacy.
- Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to Disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment.
- B cell reductive therapy in the treatment of autoimmune Diseases: a focus on monoclonal antibody treatment of rheumatoid arthritis.
- Multiplex analysis of intraCellular signaling pathways in lymphoid Cells by microbead suspension arrays.
- Pathogenesis of aryl hydrocarbon receptor-mediated development of Lymphoma is associated with increased cyclooxygenase-2 expression.
- Nondestructive identification of individual Leukemia cells by laser trapping Raman spectroscopy.
- B lymphocytes contribute to autoimmune Disease pathogenesis: current trends and clinical implications.
- Increased cyclooxygenase-2 (COX-2): a potential role in the pathogenesis of Lymphoma.
- An evaluation of barriers to accrual in the era of legislation requiring insurance coverage of Cancer clinical trial costs in California.
- Phosphorylation abnormalities: NZB mice exhibit a B-Cell signalling defect.
- Prognostic factors and response to fludarabine therapy in patients with Waldenström Macroglobulinemia: results of United States intergroup trial (Southwest Oncology Gr...
- Radioimmunotherapy: potential as a therapeutic strategy in non-Hodgkin''s Lymphoma.
- CD22 negatively and positively regulates signal transduction through the B lymphocyte antigen receptor.
- GCKR links the Bcr-Abl oncogene and Ras to the stress-activated protein kinase pathway.
- CD22 cross-linking generates B-Cell antigen receptor-independent signals that activate the JNK/SAPK signaling cascade.
- Increased expression of the glucose-regulated gene encoding the Mr 78,000 glucose-regulated protein in chemically and radiation-transformed C3H 10T1/2 mouse embryo Cells.
- A novel human homeobox gene distantly related to proboscipedia is expressed in lymphoid and pancreatic tissues.
- Involvement of p72syk kinase, p53/56lyn kinase and phosphatidyl inositol-3 kinase in signal transduction via the human B lymphocyte antigen CD22.
- Bcl-x rather than Bcl-2 mediates CD40-dependent centrocyte survival in the germinal center.
- Tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in B-lymphocyte function.
- CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling.
- Engagement of the adhesion receptor CD22 triggers a potent stimulatory signal for B Cells and blocking CD22/CD22L interactions impairs T-Cell proliferation.
- Regulation of JAK3 expression and activation in human B Cells and B Cell malignancies.
- Adaptor proteins CRK and CRKL associate with the serine/threonine protein kinase GCKR promoting GCKR and SAPK activation.
- Prospective evaluation of Cancer clinical trial accrual patterns: identifying potential barriers to enrollment.
- Filgrastim treatment of Acute myelogenous leukemia (M7) relapse after allogeneic peripheral stem cell transplantation resulting in both graft-versus-leukemia effect wi...
- A phase 1 trial dose-escalation study of tipifarnib on a week-on, week-off schedule in relapsed, refractory or high-risk myeloid Leukemia.
- A phase I pharmacodynamic study of GTI-2040, an antisense oligonucleotide against ribonuclotide reductase, in Acute leukemias: a California Cancer Consortium study.
Schools
Keck School Of Medicine Of The Univ Of Southern California
University Of California Davis
Nih Nci
Nih Niaid
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
- Plasmapheresis
Conditions Treated
- Acute Leukemia
- Anemia
- Bladder Cancer
- Breast Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Hematology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
National Institutes of Health Clinical Center -
University of California Davis -
Keck School of Medicine of USC
Hospital
-
University of California, Davis Medical Center
Drug Facts
| NPI NUMBER | 1487639795 | |
| NPPES Provider LastName | TUSCANO | |
| NPPES Provider FirstName | JOSEPH | |
| NPPES Provider ZIPCode | 958172229 | |
| NPPES Provider State | CA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 279.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 20.0 | |
| Percent Opioid Claims | 7.17 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1487639795 |
| Last Name Of The Provider | TUSCANO |
| First Name Of The Provider | JOSEPH |
| View All |
Similar Doctors
|
|
Dr. Jocelyn Wu, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Derick H. Lau, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Primo N. Lara Jr., MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|